Introduction
The addition of O-glycosidic N-acetylglucosamine (GlcNAc) in β linkage to Ser/Thr residues (O-GlcNAc) is a dynamic posttranslational modification that occurs on numerous cytoplasmic and nuclear proteins and is distinct from complex carbohydrates synthesized in the secretory pathway (1, 2) . Proteins modified in this manner include nuclear pore components (2, 3) , transcription factors (4, 5) , cytoskeleton-associated proteins and signaling enzymes (6, 7) .
Early work on this modification suggested that it was dynamic and inducible and led to the prediction that O-GlcNAc would have a regulatory role analogous to phosphorylation (8) (9) (10) .
The cloning and characterization of enzymes responsible for the addition, O-GlcNAc transferase (OGT), and removal, neutral β-N-acetylglucosaminidase, of O-GlcNAc moieties supported this idea (11) (12) (13) . However, it has only been over the last few years that studies have begun to elucidate functional roles for O-GlcNAc and have uncovered mechanisms through which it may modulate cellular signaling pathways, and thereby cellular function, in health and disease. For example, altered O-GlcNAcylation has been extensively investigated with respect to its role in the pathogenesis of diabetes mellitus (6, (14) (15) (16) and may play a role in the etiology of certain cancers (17, 18) and Alzheimer disease (19, 20) .
Many of the approaches used to investigate O-GlcNAc function have relied on the manipulation of hexosamine biosynthesis. Approximately 2-5% of the total glucose transported into cells feeds into the hexosamine biosynthesis pathway (HBP) to form glucosamine (GlcNH 2 ) 6-phosphate (GlcNH 2 6-P) and ultimately UDP-N-acetylglucosamine (UDP-GlcNAc), the sugar donor for OGT (21) . OGT activity has been found to be sensitive to relatively small changes in substrate availability over a wide range of substrate concentrations and, additionally, recognizes in protein O-GlcNAcylation. Our data support the premise that protein O-GlcNAcylation is a highly dynamic signaling mechanism capable of rapidly transducing receptor-associated signals to influence cellular function.
Experimental Procedures
PMN Isolation-Whole blood from volunteers was obtained by venipuncture and layered onto a double discontinuous gradient formed with equal volumes of Histopaque-1077 (Sigma) over Histopaque-1119 (Sigma) (39) . The blood was centrifuged at 700 x g for 30 min. Granulocytes were collected from the 1077/1119 interface and washed in Hank's buffered salt solution buffered with 10 mM HEPES, pH 7.4 (HBSS). Contaminating red blood cells were lysed by incubation in 0.15 M NH 4 Cl/1 mM KHCO 3 / 0.1 mM EDTA for 5 min at 37 °C. The granulocytes were then washed twice in HBSS and resuspended in HBSS. The resulting samples were greater than 95% PMNs as indicated by the polymorphic nature of their nuclei (see immunofluorescence microscopy below). Cell viability was assessed through Trypan Blue (Sigma) exclusion.
Immunoblotting-2x10 6 PMNs were treated as indicated, directly lysed in 5X sample buffer (0.3 M Tris⋅HCl/5% SDS/50% glycerol/0.025% bromophenol blue/5% mercaptoethanol) and boiled for 5 min. 7.5x10 5 cell equivalents per lane (~60 µg protein) were separated by SDS-PAGE (40) and transferred to Immobilon-P (Millipore). Immunoblotting was performed using a rapid immunodetection method for Immobilon-P (Millipore Tech Note TN051). Briefly, the membranes were equilibrated in methanol and air dried. The dry membrane was incubated with mM GlcNAc was added during the primary antibody incubation. After washing, the coverslips were then blocked for 10 min at room temperature with 10% normal goat serum (Sigma)/PBS with 0.2% Tween-20 and then incubated with a 1:250 dilution of Alexa Fluor 594-cojugated goat anti-mouse IgM (Molecular Probes) in 10% normal goat serum/PBS with 0.2% Tween-20 for 45 min at room temperature. The coverslips were finally washed and mounted with 9:1 glycerol/PBS. Hoechst 33258 (Molecular Probes), 1:1000 dilution of 10 mg/ml stock, was used when indicated to counterstain nuclei (>95% of cells stained had polymorphic nuclei consistent with PMN nuclear morphology). Quantification of fMLF-induced O-GlcNAc label by fluorescence intensity was performed using Image J (NIH).
GlcNH 2 6-P and UDP-GlcNAc Determinations-5x10 6 PMNs were treated as indicated and analyzed for GlcNH 2 6-P and UDP-GlcNAc as previously described (42) . Briefly, the cells were centrifuged, and the pellet extracted with 100 µl 0.3 M perchloric acid. The extract was centrifuged for 10 min at 4 °C at 14,000 x g, and 200 µl of 1:4 trioctylamine:1,1,2-trichlorotrifluoroethane (freon) was mixed with the resulting supernatant. The mixture was centrifuged for 5 min at 4 °C at 14,000 x g, and the aqueous phase (top) was stored at -80 °C for up to one week. For HPLC determination of UDP-GlcNAc the aqueous phase was run on a strong anion exchange column (Partisil SAX; Thermo) with the detector set to 262 nm. Respiratory Burst Assays-PMN respiratory burst activity was assessed by luminol-dependent chemiluminescence (45) . The PMNs were pretreated where indicated, and all samples were rapidly washed before being assayed (the presence of free GlcNH 2 in the chemiluminescence buffer was found to inhibit chemiluminescence readings). Samples were prepared by mixing 10 6 washed PMNs into HBSS/10 µM luminol/100 µM sodium azide/10 U/ml horseradish peroxidase. Chemiluminescence was monitored at room temperature in a tube-based luminometer (Optocomp 1; MGM Instruments) without stirring or shaking. Baseline readings were established over 30 sec followed by stimulation with fMLF as indicated. Although the O-GlcNAc-specific antibody CTD110.6 has been successfully used previously in immunoblot and Elisa-based assays (41), it has not been evaluated with respect to immunocytochemical microscopy. We developed a protocol using CTD110.6 in a fluorescencebased immunocytochemical assay as an alternate and complementary method of examining changes in O-GlcNAc modifications. 100 nM fMLF increased O-GlcNAc over 2 min of stimulation ( Fig. 2A ). We obtained low background, antibody-specific signal using formaldehyde fixation followed by methanol permeation. The permeation agent was a critical variable in developing this assay, as commonly used agents such as Triton and acetone yielded high non-specific backgrounds (data not shown). The agonist-induced CTD110.6 signal was specific for protein-associated O-GlcNAc, as it was competitively blocked by free GlcNAc.
Results

PMNs display rapid agonist-induced changes in
These results paralleled our immunoblot data. would have in PMNs. GlcNH 2 is an exogenous substrate for the HBP that is commonly used to drive HBP-dependent O-GlcNAcylation (6, 21, 23) . On entering a cell it is phosphorylated by hexokinase to form GlcNH 2 6-P, thus directly entering the HBP. Further processing yields UDPGlcNAc, the HBP product necessary for O-GlcNAcylation.
We examined GlcNH 2 6-P and UDP-GlcNAc levels in GlcNH 2 -treated PMNs by HPLC.
Resting GlcNH 2 6-P levels were about 20-fold less than UDP-GlcNAc levels, ~0.06 pmol/mg protein versus ~1.4 nmol/mg protein (Fig. 4) . UDP-GlcNAc was the predominant sugar nucleotide in PMNs and was a major phospho-nucleotide, along with ADP, ATP and UDPglucose (data not shown). This suggests that a relatively abundant pool of UDP-GlcNAc is important for normal PMN physiology and function. Short duration treatments with 10 mM GlcNH 2 led to the production of both GlcNH 2 6-P and UDP-GlcNAc. GlcNH 2 6-P levels rose following GlcNH 2 treatment, doubling over 2 min and increasing ~8-fold by 60 min (Fig. 4A ),
indicating that GlcNH 2 rapidly entered the cells and was quickly phosphorylated by hexokinase.
The increase in UDP-GlcNAc levels clearly followed the rise in GlcNH 2 6-P (Fig. 4B ), as might be expected for HBP processing. Although the percent increase in UDP-GlcNAc was significantly smaller than that for GlcNH 2 6-P at any given time (for example, 60% versus 700% after 60 min), the molar increase in UDP-GlcNAc was greater than that for GlcNH 2 6-P (an increases of 0.83 vs. 0.42 nmol/mg protein after 60 min). No drop in cellular ATP levels was observed for GlcNH 2 treatment (data not shown). In fMLF-treated cells there was no apparent change in GlcNH 2 6-P or UDP-GlcNAc levels with stimulation (data not shown). To investigate the relationship between increased UDP-GlcNAc and protein O-GlcNAc in our system, aliquots from the same PMN preparation were taken for each experimental condition (Fig. 5B) . These experiments used PMNs from a single donor and cell isolation, eliminating day-to-day and inter-donor variation. We found that significant changes in GlcNH 2 -induced protein O-GlcNAcylation corresponded with only modest increases in UDP-GlcNAc. Cells treated with 10 mM GlcNH 2 for 30 min showed a significantly increased fluorescent signal versus untreated controls (Fig. 5C ). The signal was specific for O-GlcNAc, as it was competitively blocked by free GlcNAc. These results paralleled and confirmed our immunoblot data. Interestingly, the GlcNH 2 -associated increase in CTD110.6 label was, as it was by immunoblot, grossly similar to that observed for fMLF (refer to Figs. 2A and 2B ). The effects of GlcNH 2 were most readily apparent in the cytoplasm, with a relatively large increase in the punctate label. The more diffuse and homogenous labeling pattern, present in the cytosol and the nucleus, was also increased by GlcNH 2 treatment.
UDP-GlcNAc levels and O-GlcNAcylation
GlcNH 2 treatment amplifies fMLF-induced protein O-GlcNAcylation. We next asked if
GlcNH 2 was effective in conjunction with fMLF as a means of manipulating agonist-associated O-GlcNAcylation. Combined GlcNH 2 and agonist treatments were additive for OGlcNAcylation, with short duration GlcNH 2 pre-treatments, which do not significantly increase O-GlcNAc by themselves (refer to Fig. 5B ), leading to noticeably increased fMLF-induced OGlcNAc (Fig. 6 ). These additive effects were most clearly evident at higher GlcNH 2 concentrations. These experiments also confirmed that the pattern of O-GlcNAcylation due to fMLF approximated that observed for GlcNH 2 . treatment on agonist-induced respiratory burst (defined by the production of reactive oxygen species) and chemotactic activities. GlcNH 2 pre-treatments of various durations, 10-120 min, and concentrations, 0.1-10 mM GlcNH 2 , had little effect (in all cases statistically non-significant, p>0.05) on the respiratory burst elicited by 100 nM fMLF in luminol-dependent assays (Fig. 7A ).
There was a trend toward reduced and slower onset activity for short duration GlcNH 2 pretreatments, 10 and 30 min, and somewhat enhanced and faster onset activity for long duration pre-treatments, 120 min. The GlcNH 2 treatments did not affect cell viability or morphology (data not shown).
An initial assessment of the effect of short duration GlcNH 2 pre-treatment, 10 mM for 30 min, on chemotaxis revealed that GlcNH 2 significantly increases both basal and fMLF-induced activity (60% and 63% respectively) in simple 45 min Boyden chamber-type assays (Fig. 7B ).
These data supported the possibility that GlcNH 2 selectively modulates only certain aspects of neutrophil physiology. We further defined GlcNH 2 -enhanced chemotaxis by altering both the duration of GlcNH 2 pre-treatment and the concentration of GlcNH 2 used (Fig. 7C) . The chemotactic response was dependent on the GlcNH 2 dose and pre-treatment duration: higher doses and longer pre-treatments clearly enhanced chemotactic activity toward fMLF, while lower doses and shorter pre-treatments were without significant effect. Significantly enhanced chemotaxis was observed for all GlcNH 2 doses tested by 120 min of pre-treatment, with 10 mM We felt it essential to establish that exogenous GlcNH 2 would be metabolized by the HBP in a comparable time frame. Short-term GlcNH 2 treatments increased the levels of HBP metabolites, first GlcNH 2 6-P and then UDP-GlcNAc. UDP-GlcNAc formation was dependent shown to be sensitive to small changes in UDP-GlcNAc (22) . In addition, the observed levels of UDP-GlcNAc reflect net changes and not just UDP-GlcNAc synthesis, and thus do not take into account its utilization, which may be significant as the length of GlcNH 2 treatment increases.
Furthermore, the observed levels may not accurately reflect localized concentration changes that could occur in particular cellular compartments. This is relevant because cytosolic levels of UDP-GlcNAc are thought to be 10-20 times lower than ER/Golgi levels (50,51).
We also combined GlcNH 2 and agonist treatments, and found additive increases in O- 
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Rapid agonist-induced O-GlcNAcylation
